Escolar Documentos
Profissional Documentos
Cultura Documentos
worth $2-4bn and novel treatments for slow down the progression of injury are much in demand. This will ensure that NeuroSTAT gains market share, considering its neuroprotective benefits.
Haemorrhage/Retinopathy of Prematurity Hypoxic-ischemic Encephalopathy I Dec 2012 University of California, San Francisco/ Thrasher Research Fund/ Children's Hospital & Research Center Oakland/ University of Washington/ Santa Clara Valley Health & Hospital System Hypoxic Ischemic Encephalopathy Source: visiongain 2012 I/II March 2014 University of Utah
www.visiongain.com
Page 51
http://www.bioportfolio.net/report/13642-neuroprotective-products-world-marketprospects-2012.html
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.04 0.05 0.07 0.10 4.00 4.00 7.00 8.00 10.00 14.00 20.00 20.00 35.00 35.00 40.00 6.57 17.25
www.visiongain.com
Page 52
http://www.bioportfolio.net/report/13642-neuroprotective-products-world-marketprospects-2012.html